- Previous Close
16.380 - Open
16.460 - Bid 16.000 x --
- Ask 16.500 x --
- Day's Range
16.180 - 16.600 - 52 Week Range
13.000 - 29.800 - Volume
124,000 - Avg. Volume
254,271 - Market Cap (intraday)
5.721B - Beta (5Y Monthly) -0.65
- PE Ratio (TTM)
24.63 - EPS (TTM)
0.670 - Earnings Date --
- Forward Dividend & Yield 0.63 (3.82%)
- Ex-Dividend Date May 28, 2024
- 1y Target Est
--
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding company, engages in the research, development, manufacture, and commercialization of interventional medical devices worldwide. The company offers congenital heart diseases interventional treatment solutions, including atrial septal defect, ventricular septal defect, and patent ductus arteriosus occluder products; delivery systems; and snare products. It also provides cardioembolic stroke prevention solutions, such as left atrial appendage and patent foramen ovale occluder products; treatment of valvular disease solutions comprising aortic valve products, mitral valve products, tricuspid valve products, pulmonary valve products, and procedural accessories; and vascular plugs and interatrial shunt devices. The company offers its products primarily to distributors and hospitals. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. is a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.
www.scientechmed.comRecent News: 2291.HK
View MorePerformance Overview: 2291.HK
Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2291.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2291.HK
View MoreValuation Measures
Market Cap
5.68B
Enterprise Value
4.29B
Trailing P/E
24.64
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.10
Price/Book (mrq)
2.85
Enterprise Value/Revenue
9.89
Enterprise Value/EBITDA
16.12
Financial Highlights
Profitability and Income Statement
Profit Margin
52.90%
Return on Assets (ttm)
7.23%
Return on Equity (ttm)
11.64%
Revenue (ttm)
408.64M
Net Income Avi to Common (ttm)
216.19M
Diluted EPS (ttm)
0.670
Balance Sheet and Cash Flow
Total Cash (mrq)
1.32B
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
285.72M